Literature DB >> 10598194

Foregut carcinoids: a clinical and biochemical analysis.

P M Kirshbom1, A R Kherani, M W Onaitis, A Hata, T E Kehoe, C Feldman, J M Feldman, D S Tyler.   

Abstract

BACKGROUND: Gastrointestinal foregut carcinoids make up a small percentage (3% to 6%) of all reported carcinoids. Because these tumors are so uncommon, comparisons between the subtypes have been difficult. The goal of this study was to compare the hormonal and clinical characteristics of gastric, duodenal, and pancreatic carcinoids.
METHODS: A prospective database of approximately 750 carcinoid patients seen by one author over 25 years was reviewed, and the 104 patients with gastric (33), duodenal (17), or pancreatic (54) carcinoids were selected as the subgroup for analysis. These patients were compared with regard to hormone levels, clinical course, treatment, and survival.
RESULTS: Duodenal carcinoids exhibited significantly lower serotoninergic hormone levels than did the gastric and pancreatic carcinoids (urine 5-hydroxyindoleacetic acid [mg/24 h], 5 +/- 1 vs 16 +/- 5 and 47 +/- 12, respectively, P = .03). Pancreatic carcinoids presented with more advanced stage (distant metastases 87% vs 42% and 20% for gastric and duodenal, respectively) and had worse outcomes than patients with gastric and duodenal tumors with 10-year survivals of 10%, 59%, and 58%, respectively (P = .003).
CONCLUSIONS: Pancreatic carcinoids produce higher levels of serotoninergic hormones and have a significantly higher stage and worse outcome than other foregut carcinoids. This study demonstrates that the organ of origin is an important determinant of hormonal activity and clinical course for patients with foregut carcinoids.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10598194     DOI: 10.1067/msy.2099.101430

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  7 in total

1.  Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours.

Authors:  J K Ramage; A H G Davies; J Ardill; N Bax; M Caplin; A Grossman; R Hawkins; A M McNicol; N Reed; R Sutton; R Thakker; S Aylwin; D Breen; K Britton; K Buchanan; P Corrie; A Gillams; V Lewington; D McCance; K Meeran; A Watkinson
Journal:  Gut       Date:  2005-06       Impact factor: 23.059

Review 2.  Small bowel neuroendocrine tumors: From pathophysiology to clinical approach.

Authors:  Sofia Xavier; Bruno Rosa; José Cotter
Journal:  World J Gastrointest Pathophysiol       Date:  2016-02-15

3.  Gastrointestinal carcinoids: characterization by site of origin and hormone production.

Authors:  M W Onaitis; P M Kirshbom; T Z Hayward; F J Quayle; J M Feldman; H F Seigler; D S Tyler
Journal:  Ann Surg       Date:  2000-10       Impact factor: 12.969

Review 4.  Management of gastric and duodenal neuroendocrine tumors.

Authors:  Yuichi Sato; Satoru Hashimoto; Ken-Ichi Mizuno; Manabu Takeuchi; Shuji Terai
Journal:  World J Gastroenterol       Date:  2016-08-14       Impact factor: 5.742

5.  Gastrointestinal carcinoid tumors: factors that predict outcome.

Authors:  Jamie J Van Gompel; Rebecca S Sippel; Tom F Warner; Herbert Chen
Journal:  World J Surg       Date:  2004-03-04       Impact factor: 3.352

6.  Is laparoscopic resection adequate in patients with neuroendocrine pancreatic tumors?

Authors:  Laureano Fernández-Cruz; Laia Blanco; Rebeca Cosa; Héctor Rendón
Journal:  World J Surg       Date:  2008-05       Impact factor: 3.352

Review 7.  Pancreatic carcinoids (serotonin-producing pancreatic neuroendocrine neoplasms): Report of 5 cases and review of the literature.

Authors:  Nikolaos Tsoukalas; Eleftherios Chatzellis; Dimitra Rontogianni; Krystallenia I Alexandraki; Georgios Boutzios; Anna Angelousi; Gregory Kaltsas
Journal:  Medicine (Baltimore)       Date:  2017-04       Impact factor: 1.889

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.